Biochemical insights into cannabidiol–endocannabinoid system interactions in the regulation of metabolic pathways
DOI:
https://doi.org/10.20450/mjcce.2025.3278Keywords:
CB1 and CB2 receptors, Diabetes mellitus (DM), Metabolic syndrome (CKM syndrome), Insulin resistance, Glucose metabolism, Cardiovascular risk, Inflammation, Oxidative stress, Lipid metabolismAbstract
Cannabidiol (CBD), a non-psychoactive phytocannabinoid from Cannabis sativa, has emerged as an important compound of interest in biochemical and pharmaceutical research. Its molecular activity is closely linked to the endocannabinoid system (ECS), which plays a central role in the regulation of metabolic homeostasis. Dysregulation of the ECS has been associated with insulin resistance, lipid imbalance, obesity, and increased cardiovascular risk. This review summarizes the current biochemical evidence on the mechanisms by which CBD modulates metabolic pathways through interactions with cannabinoid receptors and related molecular targets. Special emphasis is placed on the antioxidant and anti-inflammatory properties of CBD, its capacity to influence mitochondrial function, and its impact on glucose and lipid metabolism. Furthermore, this review discusses the influence of physicochemical factors, such as bioavailability and route of administration, on the pharmacokinetic and pharmacodynamic behavior of CBD. Potential interactions with other biomolecules and therapeutic agents are also considered, highlighting the need for systematic biochemical and pharmacological evaluation. Overall, the synthesis of the available literature indicates that CBD is a promising candidate for further biochemical and preclinical studies aimed at elucidating its regulatory role in metabolic processes and its potential for the development of novel therapeutic strategies.
References
(1) Kirilov, B.; Zhelyazkova, M.; Petkova-Gueorguieva, E.; Momekov, G. Regulation and Marketing of Cannabidiol-Containing Products in European Countries. Pharmacists’ Knowledge in Bulgaria. Biotechnology & Biotechnological Equipment 2020, 34 (1), 1158–1165. https://doi.org/10.1080/13102818.2020.1824620.
(2) Adams, R.; Hunt, M.; Clark, J. H. Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. I. J. Am. Chem. Soc. 1940, 62 (1), 196–200.
https://doi.org/10.1021/ja01858a058
(3) Jacob, A.; Todd, A. R. 119. Cannabis Indica. Part II. Isolation of Cannabidiol from Egyptian Hashish. Observations on the Structure of Cannabinol. J. Chem. Soc. 1940, No. 0, 649–653.
https://doi.org/10.1039/JR9400000649.
(4) Wiciński, M.; Fajkiel-Madajczyk, A.; Kurant, Z.; Gryczka, K.; Kurant, D.; Szambelan, M.; Malinowski, B.; Falkowski, M.; Zabrzyński, J.; Słupski, M. The Use of Cannabidiol in Metabolic Syndrome—An Opportunity to Improve the Patient’s Health or Much Ado about Nothing? JCM 2023, 12 (14), 4620. https://doi.org/10.3390/jcm12144620
(5) Zorzenon, M. R. T.; Santiago, A. N.; Mori, M. A.; Piovan, S.; Jansen, C. A.; Perina Padilha, M. E.; Ciotta, S. R.; Cezar De Freitas Mathias, P.; Guimarães, F. S.; Weffort De Oliveira, R. M.; Milani, P. G.; Mareze-Costa, C. E. Cannabidiol Improves Metabolic Dysfunction in Middle-Aged Diabetic Rats Submitted to a Chronic Cerebral Hypoperfusion. Chemico-Biological Interactions 2019, 312, 108819.
https://doi.org/10.1016/j.cbi.2019.108819
(6) Bielawiec, P.; Harasim-Symbor, E.; Chabowski, A. Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol. Front Endocrinol (Lausanne) 2020, 11, 114.
https://doi.org/10.3389/fendo.2020.00114
(7) Montoya-Alatriste, C. A.; Alarcon-Aguilar, F. J. Cannabis and Cannabinoids as an Alternative Remedy in Metabolic Syndrome. Braz. J. Pharm. Sci. 2022, 58, e20161. https://doi.org/10.1590/s2175-97902022e20161
(8) ElSohly, M. A.; Radwan, M. M.; Gul, W.; Chandra, S.; Galal, A. Phytochemistry of Cannabis Sativa L. Prog Chem Org Nat Prod 2017, 103, 1–36.
https://doi.org/10.1007/978-3-319-45541-9_1
(9) Devsi, A.; Kiyota, B.; Ouellette, T.; Hegle, A. P.; Rivera-Acevedo, R. E.; Wong, J.; Dong, Y.; Pugsley, M. K.; Fung, T. A Pharmacological Characterization of Cannabis Sativa Chemovar Extracts. J Cannabis Res 2020, 2 (1), 17. https://doi.org/10.1186/s42238-020-00026-0
(10) Expert Committee on Drug Dependence (ECD). WHO Expert Committee on Drug Dependence Critical Review Cannabis and Cannabis Resin; World Health Organisation, 2018.
https://www.who.int/publications/m/item/cannabis-and-cannabis-resin.
(11) Halawa, O. I.; Furnish, T. J.; Wallace, M. S. Chapter 56 - Role of Cannabinoids in Pain Management. In Essentials of Pain Medicine (Fourth Edition); Benzon, H. T., Raja, S. N., Liu, S. S., Fishman, S. M., Cohen, S. P., Eds.; Elsevier, 2018; pp 509-520.e2.
https://doi.org/10.1016/B978-0-323-40196-8.00056-5
(12) Meccariello, R.; Santoro, A.; D’Angelo, S.; Morrone, R.; Fasano, S.; Viggiano, A.; Pierantoni, R. The Epigenetics of the Endocannabinoid System. Int J Mol Sci 2020, 21 (3), 1113. https://doi.org/10.3390/ijms21031113
(13) Farokhnia, M.; McDiarmid, G. R.; Newmeyer, M. N.; Munjal, V.; Abulseoud, O. A.; Huestis, M. A.; Leggio, L. Effects of Oral, Smoked, and Vaporized Cannabis on Endocrine Pathways Related to Appetite and Metabolism: A Randomized, Double-Blind, Placebo-Controlled, Human Laboratory Study. Transl Psychiatry 2020, 10 (1), 71.
https://doi.org/10.1038/s41398-020-0756-3
(14) Fasinu, P. S.; Phillips, S.; ElSohly, M. A.; Walker, L. A. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents. Pharmacotherapy 2016, 36 (7), 781–796. https://doi.org/10.1002/phar.1780
(15) Pourseyed Lazarjani, M.; Torres, S.; Hooker, T.; Fowlie, C.; Young, O.; Seyfoddin, A. Methods for Quantification of Cannabinoids: A Narrative Review. J Cannabis Res 2020, 2 (1), 35. https://doi.org/10.1186/s42238-020-00040-2
(16) Qamar, S.; Manrique, Y. J.; Parekh, H. S.; Falconer, J. R. Development and Optimization of Supercritical Fluid Extraction Setup Leading to Quantification of 11 Cannabinoids Derived from Medicinal Cannabis. Biology (Basel) 2021, 10 (6), 481.
https://doi.org/10.3390/biology10060481.
(17) Kornpointner, C.; Martinez, A. S.; Schnürch, M.; Halbwirth, H.; Bica-Schröder, K. Combined Ionic Liquid and Supercritical Carbon Dioxide Based Dynamic Extraction of Six Cannabinoids from Cannabis Sativa L. Green Chem. 2021, 23 (24), 10079–10089. https://doi.org/10.1039/D1GC03516A.
(18) Stefkov, G.; Cvetkovikj Karanfilova, I.; Stoilkovska Gjorgievska, V.; Trajkovska, A.; Geskovski, N.; Karapandzova, M.; Kulevanova, S. Analytical Techniques for Phytocannabinoid Profiling of Cannabis and Cannabis-Based Products—A Comprehensive Review. Molecules 2022, 27 (3), 975.
https://doi.org/10.3390/molecules27030975.
(19) Citti, C.; Braghiroli, D.; Vandelli, M. A.; Cannazza, G. Pharmaceutical and Biomedical Analysis of Cannabinoids: A Critical Review. J. Pharm. Biomed. Anal. 2018, 147, 565–579.
https://doi.org/10.1016/j.jpba.2017.06.003
(20) Geskovski, N.; Stefkov, G.; Gigopulu, O.; Stefov, S.; Huck, C. W.; Makreski, P. Mid-Infrared Spectroscopy as Process Analytical Technology Tool for Estimation of THC and CBD Content in Cannabis Flowers and Extracts. Spectrochim. Acta A 2021, 251, 119422. https://doi.org/10.1016/j.saa.2020.119422
(21) Gigopulu, O.; Geskovski, N.; Stefkov, G.; Stoilkovska Gjorgievska, V.; Slaveska Spirevska, I.; Huck, C. W.; Makreski, P. A Unique Approach for In-Situ Monitoring of the THCA Decarboxylation Reaction in Solid State. Spectrochim. Acta A 2022, 267, 120471.
https://doi.org/10.1016/j.saa.2021.120471
(22) Gigopulu, O.; Geskovski, N.; Stefkov, G.; Panovska, A. P.; Piponski, M.; Spirevska, I. S.; Makreski, P. Real-Time Monitoring of CBDA Decarboxylation in Solid State and Cannabis Flowers Using Mid Infrared Spectroscopy Coupled with Multivariate Analysis. Vibrational Spectroscopy 2024, 103728.
https://doi.org/10.1016/j.vibspec.2024.103728
(23) Kumawat, V. S.; Kaur, G. Therapeutic Potential of Cannabinoid Receptor 2 in the Treatment of Diabetes Mellitus and Its Complications. European Journal of Pharmacology 2019, 862, 172628.
https://doi.org/10.1016/j.ejphar.2019.172628
(24) Frisher, M.; White, S.; Varbiro, G.; Voisey, C.; Perumal, D.; Crome, I.; Khideja, N.; Bashford, J. The Role of Cannabis and Cannabinoids in Diabetes. The British Journal of Diabetes & Vascular Disease 2010, 10, 267–273. https://doi.org/10.1177/1474651410385860
(25) Atalay, S.; Jarocka-Karpowicz, I.; Skrzydlewska, E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants (Basel) 2019, 9 (1), 21.
https://doi.org/10.3390/antiox9010021
(26) Dörnyei, G.; Vass, Z.; Juhász, C. B.; Nádasy, G. L.; Hunyady, L.; Szekeres, M. Role of the Endocannabinoid System in Metabolic Control Processes and in the Pathogenesis of Metabolic Syndrome: An Update. Biomedicines 2023, 11 (2), 306.
https://doi.org/10.3390/biomedicines11020306
(27) Gruden, G.; Barutta, F.; Kunos, G.; Pacher, P. Role of the Endocannabinoid System in Diabetes and Diabetic Complications. Br J Pharmacol 2016, 173 (7), 1116–1127. https://doi.org/10.1111/bph.13226.
(28) Lu, H.-C.; Mackie, K. An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry 2016, 79 (7), 516–525.
https://doi.org/10.1016/j.biopsych.2015.07.028
(29) Braile, M.; Marcella, S.; Marone, G.; Galdiero, M. R.; Varricchi, G.; Loffredo, S. The Interplay between the Immune and the Endocannabinoid Systems in Cancer. Cells 2021, 10 (6), 1282.
https://doi.org/10.3390/cells10061282
(30) Howlett, A. C.; Abood, M. E. CB1 and CB2 Receptor Pharmacology. Adv Pharmacol 2017, 80, 169–206. https://doi.org/10.1016/bs.apha.2017.03.007
(31) Onaivi, E. S.; Ishiguro, H.; Liu, Q.-R. Chapter 18 - Future Perspectives: Cannabinoid CB2 Receptor Ligands and Their Therapeutic Potential in Mental Diseases. In Cannabinoids in Neurologic and Mental Disease; Fattore, L., Ed.; Academic Press: San Diego, 2015; pp 425–444.
https://doi.org/10.1016/B978-0-12-417041-4.00018-7
(32) Bie, B.; Wu, J.; Foss, J. F.; Naguib, M. An Overview of the Cannabinoid Type 2 (CB2) Receptor System and Its Therapeutic Potential. Curr Opin Anaesthesiol 2018, 31 (4), 407–414.
https://doi.org/10.1097/ACO.0000000000000616
(33) Graham, E. S.; Angel, C. E.; Schwarcz, L. E.; Dunbar, P. R.; Glass, M. Detailed Characterisation of CB2 Receptor Protein Expression in Peripheral Blood Immune Cells from Healthy Human Volunteers Using Flow Cytometry. Int J Immunopathol Pharmacol 2010, 23 (1), 25–34. https://doi.org/10.1177/039463201002300103
(34) Ziring, D.; Wei, B.; Velazquez, P.; Schrage, M.; Buckley, N. E.; Braun, J. Formation of B and T Cell Subsets Require the Cannabinoid Receptor CB2. Immunogenetics 2006, 58 (9), 714–725.
https://doi.org/10.1007/s00251-006-0138-x
(35) Bermudez-Silva, F. J.; Sanchez-Vera, I.; Suárez, J.; Serrano, A.; Fuentes, E.; Juan-Pico, P.; Nadal, A.; Rodríguez de Fonseca, F. Role of Cannabinoid CB2 Receptors in Glucose Homeostasis in Rats. European Journal of Pharmacology 2007, 565 (1), 207–211. https://doi.org/10.1016/j.ejphar.2007.02.066
(36) Ibrahim, M. M.; Rude, M. L.; Stagg, N. J.; Mata, H. P.; Lai, J.; Vanderah, T. W.; Porreca, F.; Buckley, N. E.; Makriyannis, A.; Malan, T. P. CB2 Cannabinoid Receptor Mediation of Antinociception. Acute Pain 2006, 8 (3), 142.
https://doi.org/10.1016/j.acpain.2006.08.026
(37) Whiteside, G. T.; Lee, G. P.; Valenzano, K. J. The Role of the Cannabinoid CB2 Receptor in Pain Transmission and Therapeutic Potential of Small Molecule CB2 Receptor Agonists. Curr Med Chem 2007, 14 (8), 917–936. https://doi.org/10.2174/092986707780363023
(38) Mackie, K.; Ross, R. A. CB2 Cannabinoid Receptors: New Vistas. British Journal of Pharmacology 2008, 153 (2), 177–178. https://doi.org/10.1038/sj.bjp.0707617
(39) Steffens, S.; Pacher, P. Targeting Cannabinoid Receptor CB2 in Cardiovascular Disorders: Promises and Controversies. British Journal of Pharmacology 2012, 167 (2), 313–323.
https://doi.org/10.1111/j.1476-5381.2012.02042.x
(40) McKallip, R. J.; Lombard, C.; Fisher, M.; Martin, B. R.; Ryu, S.; Grant, S.; Nagarkatti, P. S.; Nagarkatti, M. Targeting CB2 Cannabinoid Receptors as a Novel Therapy to Treat Malignant Lymphoblastic Disease. Blood 2002, 100 (2), 627–634.
https://doi.org/10.1182/blood-2002-01-0098
(41) Di Filippo, C.; Rossi, F.; Rossi, S.; D’Amico, M. Cannabinoid CB2 Receptor Activation Reduces Mouse Myocardial Ischemia-Reperfusion Injury: Involvement of Cytokine/Chemokines and PMN. Journal of Leukocyte Biology 2004, 75 (3), 453–459.
https://doi.org/10.1189/jlb.0703303
(42) Cassano, T.; Villani, R.; Pace, L.; Carbone, A.; Bukke, V. N.; Orkisz, S.; Avolio, C.; Serviddio, G. From Cannabis Sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases. Front Pharmacol 2020, 11, 124.
https://doi.org/10.3389/fphar.2020.00124
(43) Katchan, V.; David, P.; Shoenfeld, Y. Cannabinoids and Autoimmune Diseases: A Systematic Review. Autoimmun Rev 2016, 15 (6), 513–528.
https://doi.org/10.1016/j.autrev.2016.02.008
(44) Kicman, A.; Toczek, M. The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease. Int J Mol Sci 2020, 21 (18), 6740.
https://doi.org/10.3390/ijms21186740
(45) Pertwee, R. G. The Diverse CB1 and CB2 Receptor Pharmacology of Three Plant Cannabinoids: Δ9-Tetrahydrocannabinol, Cannabidiol and Δ9-Tetrahydrocannabivarin. Br J Pharmacol 2008, 153 (2), 199–215. https://doi.org/10.1038/sj.bjp.0707442
(46) Fellous, T.; De Maio, F.; Kalkan, H.; Carannante, B.; Boccella, S.; Petrosino, S.; Maione, S.; Di Marzo, V.; Iannotti, F. A. Phytocannabinoids Promote Viability and Functional Adipogenesis of Bone Marrow-Derived Mesenchymal Stem Cells through Different Molecular Targets. Biochemical Pharmacology 2020, 175, 113859. https://doi.org/10.1016/j.bcp.2020.113859
(47) Global Burden of Disease Collaborative Network. Global Burden of Disease Study; Institute for Health Metrics and Evaluation, 2021.
https://vizhub.healthdata.org/gbd-results/
(48) Home; Resources; diabetes, L. with; Acknowledgement; FAQs; Contact; Policy, P. IDF Diabetes Atlas 2021 | IDF Diabetes Atlas. https://diabetesatlas.org/atlas/tenth-edition/ (accessed 2025-03-11)
(49) Vieira; Souto; Sánchez-López; Machado; Severino; Jose; Santini; Fortuna; García; Silva; Souto. Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I. Pharmaceuticals 2019, 12 (4), 152. https://doi.org/10.3390/ph12040152
(50) Zaccardi, F.; Webb, D. R.; Yates, T.; Davies, M. J. Pathophysiology of Type 1 and Type 2 Diabetes Mellitus: A 90-Year Perspective. Postgraduate Medical Journal 2016, 92 (1084), 63–69.
https://doi.org/10.1136/postgradmedj-2015-133281
(51) Porth, C. M. 3. Essentials of Pathophysiology: Concepts of Altered Health States. In AJN The American Journal of Nursing; Lippincott Williams & Wilkins, 2004; Vol. 104, p 89.
(52) Timper, K.; Donath, M. Diabetes Mellitus Type 2 - the New Face of an Old Lady. Swiss Med Wkly 2012. https://doi.org/10.4414/smw.2012.13635
(53) Di Marzo, V.; Piscitelli, F.; Mechoulam, R. Can¬nabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes. Handb Exp Pharmacol 2011, No. 203, 75–104.
https://doi.org/10.1007/978-3-642-17214-4_4
(54) Klok, M. D.; Jakobsdottir, S.; Drent, M. L. The Role of Leptin and Ghrelin in the Regulation of Food Intake and Body Weight in Humans: A Review. Obesity Reviews 2007, 8 (1), 21–34.
https://doi.org/10.1111/j.1467-789X.2006.00270.x
(55) Lazzari, P.; Sanna, A.; Mastinu, A.; Cabasino, S.; Manca, I.; Pani, L. Weight Loss Induced by Rimonabant Is Associated with an Altered Leptin Expression and Hypothalamic Leptin Signaling in Diet-Induced Obese Mice. Behavioural Brain Research 2011, 217 (2), 432–438. https://doi.org/10.1016/j.bbr.2010.11.022
(56) Valenzuela, C.; Aguirre, C.; Castillo, V.; Ronco, A. M.; Llanos, M. [A role for the endocannabinoid system in obesity]. Rev Med Chil 2010, 138 (5), 621–629.
(57) Argueta, D. A.; DiPatrizio, N. V. Peripheral Endocannabinoid Signaling Controls Hyperphagia in Western Diet-Induced Obesity. Physiology & Behavior 2017, 171, 32–39.
https://doi.org/10.1016/j.physbeh.2016.12.044
(58) Tam, J.; Hinden, L.; Drori, A.; Udi, S.; Azar, S.; Baraghithy, S. The Therapeutic Potential of Targeting the Peripheral Endocannabinoid/CB1 Receptor System. European Journal of Internal Medicine 2018, 49, 23–29. https://doi.org/10.1016/j.ejim.2018.01.009
(59) Tibiriça, E. The Multiple Functions of the Endo-cannabinoid System: A Focus on the Regulation of Food Intake. Diabetol Metab Syndr 2010, 2, 5.
https://doi.org/10.1186/1758-5996-2-5
(60) Horváth, B.; Mukhopadhyay, P.; Haskó, G.; Pacher, P. The Endocannabinoid System and Plant-Derived Cannabinoids in Diabetes and Diabetic Complications. The American Journal of Pathology 2012, 180 (2), 432–442. https://doi.org/10.1016/j.ajpath.2011.11.003
(61) Muniyappa, R.; Sable, S.; Ouwerkerk, R.; Mari, A.; Gharib, A. M.; Walter, M.; Courville, A.; Hall, G.; Chen, K. Y.; Volkow, N. D.; Kunos, G.; Huestis, M. A.; Skarulis, M. C. Metabolic Effects of Chronic Cannabis Smoking. Diabetes Care 2013, 36 (8), 2415–2422. https://doi.org/10.2337/dc12-2303
(62) Guillamat-Prats, R.; Rami, M.; Herzig, S.; Steffens, S. Endocannabinoid Signalling in Atherosclerosis and Related Metabolic Complications. Thrombosis and Haemostasis 2019, 119, 567–575.
https://doi.org/10.1055/s-0039-1678738
(63) Martín Giménez, V. M.; Noriega, S. E.; Kassuha, D. E.; Fuentes, L. B.; Manucha, W. Anandamide and Endocannabinoid System: An Attractive Therapeutic Approach for Cardiovascular Disease. Ther Adv Cardiovasc Dis 2018, 12 (7), 177–190.
https://doi.org/10.1177/1753944718773690
(64) Tam, J.; Cinar, R.; Liu, J.; Godlewski, G.; Wesley, D.; Jourdan, T.; Szanda, G.; Mukhopadhyay, B.; Chedester, L.; Liow, J.-S.; Innis, R. B.; Cheng, K.; Rice, K. C.; Deschamps, J. R.; Chorvat, R. J.; McElroy, J. F.; Kunos, G. Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance. Cell Metab 2012, 16 (2), 167–179.
https://doi.org/10.1016/j.cmet.2012.07.002
(65) Bermúdez-Silva, F. J.; Suárez, J.; Baixeras, E.; Cobo, N.; Bautista, D.; Cuesta-Muñoz, A. L.; Fuentes, E.; Juan-Pico, P.; Castro, M. J.; Milman, G.; Mechoulam, R.; Nadal, A.; Rodríguez de Fonseca, F. Presence of Functional Cannabinoid Receptors in Human Endocrine Pancreas. Diabetologia 2008, 51 (3), 476–487.
https://doi.org/10.1007/s00125-007-0890-y
(66) Rajesh, M.; Bátkai, S.; Kechrid, M.; Mukhopadhyay, P.; Lee, W.-S.; Horváth, B.; Holovac, E.; Cinar, R.; Liaudet, L.; Mackie, K.; Haskó, G.; Pacher, P. Cannabinoid 1 Receptor Promotes Cardiac Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in Diabetic Cardiomyopathy. Diabetes 2012, 61 (3), 716–727. https://doi.org/10.2337/db11-0477
(67) Cota, D.; Marsicano, G.; Tschöp, M.; Grübler, Y.; Flachskamm, C.; Schubert, M.; Auer, D.; Yassouridis, A.; Thöne-Reineke, C.; Ortmann, S.; Tomassoni, F.; Cervino, C.; Nisoli, E.; Linthorst, A. C. E.; Pasquali, R.; Lutz, B.; Stalla, G. K.; Pagotto, U. The Endogenous Cannabinoid System Affects Energy Balance via Central Orexigenic Drive and Peripheral Lipogenesis. J Clin Invest 2003, 112 (3), 423–431.
https://doi.org/10.1172/JCI17725
(68) Bergamaschi, M. M.; Queiroz, R. H. C.; Chagas, M. H. N.; de Oliveira, D. C. G.; De Martinis, B. S.; Kapczinski, F.; Quevedo, J.; Roesler, R.; Schröder, N.; Nardi, A. E.; Martín-Santos, R.; Hallak, J. E. C.; Zuardi, A. W.; Crippa, J. A. S. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. Neuropsychopharma¬cology 2011, 36 (6), 1219–1226.
https://doi.org/10.1038/npp.2011.6
(69) Iffland, K.; Grotenhermen, F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res 2017, 2 (1), 139–154.
https://doi.org/10.1089/can.2016.0034
(70) McPartland, J. M.; Duncan, M.; Di Marzo, V.; Pertwee, R. G. Are Cannabidiol and Δ(9) -Tetrahydrocan¬nabivarin Negative Modulators of the Endocannabinoid System? A Systematic Review. Br J Pharmacol 2015, 172 (3), 737–753. https://doi.org/10.1111/bph.12944
(71) Peres, F. F.; Lima, A. C.; Hallak, J. E. C.; Crippa, J. A.; Silva, R. H.; Abílio, V. C. Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders? Front. Pharmacol. 2018, 9.
https://doi.org/10.3389/fphar.2018.00482
(72) Patricio, F.; Morales-Andrade, A. A.; Patricio-Martínez, A.; Limón, I. D. Cannabidiol as a Therapeutic Target: Evidence of Its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease. Front. Pharmacol. 2020, 11. https://doi.org/10.3389/fphar.2020.595635
(73) Martinez Naya, N.; Kelly, J.; Corna, G.; Golino, M.; Abbate, A.; Toldo, S. Molecular and Cellular Mechanisms of Action of Cannabidiol. Molecules 2023, 28 (16), 5980.
https://doi.org/10.3390/molecules28165980
(74) Esposito, G.; Scuderi, C.; Valenza, M.; Togna, G. I.; Latina, V.; De Filippis, D.; Cipriano, M.; Carratù, M. R.; Iuvone, T.; Steardo, L. Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement. PLoS One 2011, 6 (12), e28668.
https://doi.org/10.1371/journal.pone.0028668
(75) Rajesh, M.; Mukhopadhyay, P.; Bátkai, S.; Haskó, G.; Liaudet, L.; Drel, V. R.; Obrosova, I. G.; Pacher, P. Cannabidiol Attenuates High Glucose-Induced Endothelial Cell Inflammatory Response and Barrier Disruption. Am J Physiol Heart Circ Physiol 2007, 293 (1), H610–H619.
https://doi.org/10.1152/ajpheart.00236.2007
(76) Després, J.-P.; Golay, A.; Sjöström, L.; Rimonabant in Obesity-Lipids Study Group. Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia. N Engl J Med 2005, 353 (20), 2121–2134. https://doi.org/10.1056/NEJMoa044537
(77) Kim, W.; Doyle, M. E.; Liu, Z.; Lao, Q.; Shin, Y.-K.; Carlson, O. D.; Kim, H. S.; Thomas, S.; Napora, J. K.; Lee, E. K.; Moaddel, R.; Wang, Y.; Maudsley, S.; Martin, B.; Kulkarni, R. N.; Egan, J. M. Cannabinoids Inhibit Insulin Receptor Signaling in Pancreatic β-Cells. Diabetes 2011, 60 (4), 1198–1209.
https://doi.org/10.2337/db10-1550
(78) Liu, J.; Zhou, L.; Xiong, K.; Godlewski, G.; Mukhopadhyay, B.; Tam, J.; Yin, S.; Gao, P.; Shan, X.; Pickel, J.; Bataller, R.; O’Hare, J.; Scherer, T.; Buettner, C.; Kunos, G. Hepatic Cannabinoid Receptor-1 Mediates Diet-Induced Insulin Resistance via Inhibition of Insulin Signaling and Clearance in Mice. Gastroenterology 2012, 142 (5), 1218-1228.e1.
https://doi.org/10.1053/j.gastro.2012.01.032
(79) Shin, H.; Han, J. H.; Yoon, J.; Sim, H. J.; Park, T. J.; Yang, S.; Lee, E. K.; Kulkarni, R. N.; Egan, J. M.; Kim, W. Blockade of Cannabinoid 1 Receptor Improves Glucose Responsiveness in Pancreatic Beta Cells. J Cell Mol Med 2018, 22 (4), 2337–2345.
https://doi.org/10.1111/jcmm.13523
(80) Motaghedi, R.; McGraw, T. E. The CB1 Endocan-nabinoid System Modulates Adipocyte Insulin Sensitivity. Obesity (Silver Spring) 2008, 16 (8), 1727–1734. https://doi.org/10.1038/oby.2008.309
(81) Hirsch, S.; Tam, J. Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome. Toxins (Basel) 2019, 11 (5), 275.
https://doi.org/10.3390/toxins11050275
(82) Di Marzo, V. The Endocannabinoid System in Obesity and Type 2 Diabetes. Diabetologia 2008, 51 (8), 1356–1367. https://doi.org/10.1007/s00125-008-1048-2
(83) Nagappan, A.; Shin, J.; Jung, M. H. Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications. Int J Mol Sci 2019, 20 (9), 2109. https://doi.org/10.3390/ijms20092109
(84) Zanoni, C.; Aiello, G.; Arnoldi, A.; Lammi, C. Hempseed Peptides Exert Hypocholesterolemic Effects with a Statin-Like Mechanism. J Agric Food Chem 2017, 65 (40), 8829–8838.
https://doi.org/10.1021/acs.jafc.7b02742
(85) Afshar, S.; Khalili, S.; Amin, G.; Abbasinazari, M. A Phase I Randomized, Double-Blind, Placebo-Controlled Study on Efficacy and Safety Profile of a Sublingually Administered Cannabidiol/Delta 9-Tetrahydrocan¬nabidiol (10: 1) Regimen in Diabetes Type 2 Patients. Iran J Pharm Res 2023, 21 (1).
https://doi.org/10.5812/ijpr-132647
(86) Abuhasira, R.; Azar, S.; Nemirovski, A.; Tam, J.; Novack, V. Herbal Cannabis Use Is Not Associated with Changes in Levels of Endocannabinoids and Metabolic Profile Alterations among Older Adults. Life 2022, 12 (10), 1539. https://doi.org/10.3390/life12101539
(87) Cusihuaman, S.; Moya-Salazar, J.; Wong-Salgado, P.; Moya-Salazar, M. M.; Cañari, B.; Chicoma-Flores, K.; Contreras-Pulache, H. Changes in High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL) and Cholesterol Concentration in Heavy Cannabis Users: A Single-Centre Study in Cusco, Peru. Processes 2022, 10 (8), 1597. https://doi.org/10.3390/pr10081597
(88) Li, J.; Bollati, C.; Bartolomei, M.; Mazzolari, A.; Arnoldi, A.; Vistoli, G.; Lammi, C. Hempseed (Cannabis Sativa) Peptide H3 (IGFLIIWV) Exerts Cholesterol-Lowering Effects in Human Hepatic Cell Line. Nutrients 2022, 14 (9), 1804. https://doi.org/10.3390/nu14091804
(89) Huang, W.; Zeng, Z.; Lang, Y.; Xiang, X.; Qi, G.; Lu, G.; Yang, X. Cannabis Seed Oil Alleviates Experimental Atherosclerosis by Ameliorating Vascular Inflammation in Apolipoprotein-E-Deficient Mice. J Agric Food Chem 2021, 69 (32), 9102–9110.
https://doi.org/10.1021/acs.jafc.0c07251
(90) Abbotts, K. S. S.; Ewell, T. R.; Butterklee, H. M.; Bomar, M. C.; Akagi, N.; Dooley, G. P.; Bell, C. Cannabidiol and Cannabidiol Metabolites: Pharmaco¬kinetics, Interaction with Food, and Influence on Liver Function. Nutrients 2022, 14 (10), 2152.
https://doi.org/10.3390/nu14102152
(91) Alonso, Y.; Miralles, C.; Algora, M. J.; Valiente-Pallejà, A.; Sánchez-Gistau, V.; Muntané, G.; Labad, J.; Vilella, E.; Martorell, L. Risk Factors for Metabolic Syndrome in Individuals with Recent-Onset Psychosis at Disease Onset and after 1-Year Follow-Up. Scientific Reports 2022, 12, 11386.
https://doi.org/10.1038/s41598-022-15479-x
(92) Reyes-Cuapio, E.; Coronado-Álvarez, A.; Quiroga, C.; Alcaraz-Silva, J.; Ruíz-Ruíz, J. C.; Imperatori, C.; Murillo-Rodríguez, E. Juvenile Cannabidiol Chronic Treatments Produce Robust Changes in Metabolic Markers in Adult Male Wistar Rats. Eur J Pharmacol 2021, 910, 174463.
https://doi.org/10.1016/j.ejphar.2021.174463
(93) Kaushal, N.; Dhadwal, S.; Kaur, P. Ameliorative Effects of Hempseed (Cannabis Sativa) against Hyper-cholesterolemia Associated Cardiovascular Changes. Nutr Metab Cardiovasc Dis 2020, 30 (2), 330–338. https://doi.org/10.1016/j.numecd.2019.09.006
(94) Ben-Cnaan, E.; Permyakova, A.; Azar, S.; Hirsch, S.; Baraghithy, S.; Hinden, L.; Tam, J. The Metabolic Efficacy of a Cannabidiolic Acid (CBDA) Derivative in Treating Diet- and Genetic-Induced Obesity. Int J Mol Sci 2022, 23 (10), 5610.
https://doi.org/10.3390/ijms23105610
(95) Stiles, E.; Alcover, K. C.; Stiles, B.; Oluwoye, O.; McDonell, M. G. Cannabis Use and Metabolic Syndrome among Clients with First Episode Psychosis. Early Interv Psychiatry 2021, 15 (4), 1051–1055.
https://doi.org/10.1111/eip.13030
(96) Ngueta, G.; Ndjaboue, R. Lifetime Marijuana Use in Relation to Insulin Resistance in Lean, Overweight, and Obese US Adults. Journal of Diabetes 2020, 12 (1), 38–47. https://doi.org/10.1111/1753-0407.12958
(97) Ngueta, G. Impact of Lifetime Marijuana Use on Fasting Plasma Insulin Levels and HOMA-IR Score in Obese Adults with and without Insulin Resistance. Acta Diabetol 2020, 57 (2), 133–140.
https://doi.org/10.1007/s00592-019-01390-x
(98) Okafor, C. N.; Plankey, M. W.; Goodman-Meza, D.; Li, M.; Bautista, K. J.; Bolivar, H.; Phyllis, T. C.; Brown, T. T.; Shoptaw, S. J. Association between Self-Reported Marijuana Use and Incident Diabetes in Women and Men with and at Risk for HIV. Drug Alcohol Depend 2020, 209, 107935.
https://doi.org/10.1016/j.drugalcdep.2020.107935
(99) Ross, J. M.; Pacheco-Colón, I.; Hawes, S. W.; Gonzalez, R. Bidirectional Longitudinal Associations Between Cannabis Use and Body Mass Index Among Adolescents. Cannabis Cannabinoid Res 2020, 5 (1), 81–88. https://doi.org/10.1089/can.2019.0091
(100) Roberts, C. A.; Jager, G.; Christiansen, P.; Kirkham, T. C. Exploring the Munchies: An Online Survey of Users’ Experiences of Cannabis Effects on Appetite and the Development of a Cannabinoid Eating Experience Questionnaire. J Psychopharmacol 2019, 33 (9), 1149–1159. https://doi.org/10.1177/0269881119862526
(101) Alshaarawy, O.; Sidney, S.; Auer, R.; Green, D.; Soliman, E. Z.; Goff, D. C.; Anthony, J. C. Cannabis Use and Markers of Systemic Inflammation: The Coronary Artery Risk Development in Young Adults Study. The American Journal of Medicine 2019, 132 (11), 1327-1334.e1. https://doi.org/10.1016/j.amjmed.2019.04.045
(102) Kalla, A.; Krishnamoorthy, P. M.; Gopalakrishnan, A.; Figueredo, V. M. Cannabis Use Predicts Risks of Heart Failure and Cerebrovascular Accidents: Results from the National Inpatient Sample. J Cardiovasc Med (Hagerstown) 2018, 19 (9), 480–484.
https://doi.org/10.2459/JCM.0000000000000681
(103) Auer, R.; Sidney, S.; Goff, D.; Vittinghoff, E.; Pletcher, M. J.; Allen, N. B.; Reis, J. P.; Lewis, C. E.; Carr, J.; Rana, J. S. Lifetime Marijuana Use and Subclinical Atherosclerosis: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Addiction 2018, 113 (5), 845–856.
https://doi.org/10.1111/add.14110
(104) Chia, C. W.; Carlson, O. D.; Liu, D. D.; González-Mariscal, I.; Santa-Cruz Calvo, S.; Egan, J. M. Incretin Secretion in Humans Is under the Influence of Cannabinoid Receptors. Am J Physiol Endocrinol Metab 2017, 313 (3), E359–E366.
https://doi.org/10.1152/ajpendo.00080.2017
(105) Rossi, F.; Punzo, F.; Umano, G. R.; Argenziano, M.; Miraglia Del Giudice, E. Role of Cannabinoids in Obesity. International Journal of Molecular Sciences 2018, 19 (9), 2690.
https://doi.org/10.3390/ijms19092690
(106) Nogueiras, R.; Diaz-Arteaga, A.; Lockie, S. H.; Velásquez, D. A.; Tschop, J.; López, M.; Cadwell, C. C.; Diéguez, C.; Tschöp, M. H. The Endocannabinoid System: Role in Glucose and Energy Metabolism. Pharmacological Research 2009, 60 (2), 93–98. https://doi.org/10.1016/j.phrs.2009.04.004
(107) Silvestri, C.; Paris, D.; Martella, A.; Melck, D.; Guadagnino, I.; Cawthorne, M.; Motta, A.; Marzo, V. D. Two Non-Psychoactive Cannabinoids Reduce Intra-cellular Lipid Levels and Inhibit Hepatosteatosis. Journal of Hepatology 2015, 62 (6), 1382–1390. https://doi.org/10.1016/j.jhep.2015.01.001
(108) Chaves, Y. C.; Genaro, K.; Crippa, J. A.; da Cunha, J. M.; Zanoveli, J. M. Cannabidiol Induces Antidepressant and Anxiolytic‐like Effects in Experimental Type-1 Diabetic Animals by Multiple Sites of Action. Metab Brain Dis 2021, 36 (4), 639–652.
https://doi.org/10.1007/s11011-020-00667-3
(109) Kabir, M.; Iyer, M. S.; Richey, J. M.; Woolcott, O. O.; Asare Bediako, I.; Wu, Q.; Kim, S. P.; Stefanovski, D.; Kolka, C. M.; Hsu, I. R.; Catalano, K. J.; Chiu, J. D.; Ionut, V.; Bergman, R. N. CB1R Antagonist Increases Hepatic Insulin Clearance in Fat-Fed Dogs Likely via Upregulation of Liver Adiponectin Receptors. Am J Physiol Endocrinol Metab 2015, 309 (8), E747-758. https://doi.org/10.1152/ajpendo.00196.2015
(110) Berk, K.; Konstantynowicz-Nowicka, K.; Charytoniuk, T.; Harasim-Symbor, E.; Chabowski, A. Distinct Effects of Cannabidiol on Sphingolipid Metabolism in Subcutaneous and Visceral Adipose Tissues Derived from High-Fat-Diet-Fed Male Wistar Rats. Int. J. Mol. Sci. 2022, 23 (10), 5382.
https://doi.org/10.3390/ijms23105382
(111) Jadoon, K. A.; Ratcliffe, S. H.; Barrett, D. A.; Thomas, E. L.; Stott, C.; Bell, J. D.; O’Sullivan, S. E.; Tan, G. D. Efficacy and Safety of Cannabidiol and Tetrahydro-cannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care 2016, 39 (10), 1777–1786.
https://doi.org/10.2337/dc16-0650
(112) Weiss, L.; Zeira, M.; Reich, S.; Har-Noy, M.; Mechoulam, R.; Slavin, S.; Gallily, R. Cannabidiol Lowers Incidence of Diabetes in Non-Obese Diabetic Mice. Autoimmunity 2006, 39 (2), 143–151.
https://doi.org/10.1080/08916930500356674
(113) Zhang, J.; Lin, C.; Jin, S.; Wang, H.; Wang, Y.; Du, X.; Hutchinson, M. R.; Zhao, H.; Fang, L.; Wang, X. The Pharmacology and Therapeutic Role of Cannabidiol in Diabetes. Exploration (Beijing) 2023, 3 (5), 20230047. https://doi.org/10.1002/EXP.20230047
(114) Henshaw, F. R.; Dewsbury, L. S.; Lim, C. K.; Steiner, G. Z. The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. Cannabis Cannabinoid Res 2021, 6 (3), 177–195. https://doi.org/10.1089/can.2020.0105
(115) Shayesteh, M. R. H.; Haghi-Aminjan, H.; Mousavi, M. J.; Momtaz, S.; Abdollahi, M. The Protective Mechanism of Cannabidiol in Cardiac Injury: A Systematic Review of Non-Clinical Studies. http://www.eurekaselect.com 2024
(116) Weiss, L.; Zeira, M.; Reich, S.; Slavin, S.; Raz, I.; Mechoulam, R.; Gallily, R. Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice. Neuropharmacology 2008, 54 (1), 244–249.
https://doi.org/10.1016/j.neuropharm.2007.06.029
(117) Chaves, Y. C.; Genaro, K.; Stern, C. A.; de Oliveira Guaita, G.; de Souza Crippa, J. A.; da Cunha, J. M.; Zanoveli, J. M. Two-Weeks Treatment with Cannabidiol Improves Biophysical and Behavioral Deficits Associated with Experimental Type-1 Diabetes. Neuroscience Letters 2020, 729, 135020.
https://doi.org/10.1016/j.neulet.2020.135020
(118) Gorelick, J.; Assa-Glazer, T.; Zandani, G.; Altberg, A.; Sela, N.; Nyska, A.; Madar, Z. THC and CBD Affect Metabolic Syndrome Parameters Including Microbiome in Mice Fed High Fat-Cholesterol Diet. J Cannabis Res 2022, 4 (1), 27.
https://doi.org/10.1186/s42238-022-00137-w
(119) Rakotoarivelo, V.; Sihag, J.; Flamand, N. Role of the Endocannabinoid System in the Adipose Tissue with Focus on Energy Metabolism. Cells 2021, 10 (6), 1279. https://doi.org/10.3390/cells10061279
(120) Ndumele, C. E.; Rangaswami, J.; Chow, S. L.; Neeland, I. J.; Tuttle, K. R.; Khan, S. S.; Coresh, J.; Mathew, R. O.; Baker-Smith, C. M.; Carnethon, M. R.; Despres, J.-P.; Ho, J. E.; Joseph, J. J.; Kernan, W. N.; Khera, A.; Kosiborod, M. N.; Lekavich, C. L.; Lewis, E. F.; Lo, K. B.; Ozkan, B.; Palaniappan, L. P.; Patel, S. S.; Pencina, M. J.; Powell-Wiley, T. M.; Sperling, L. S.; Virani, S. S.; Wright, J. T.; Rajgopal Singh, R.; Elkind, M. S. V.; American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation 2023, 148 (20), 1606–1635. https://doi.org/10.1161/CIR.0000000000001184
(121) Sierra, S.; Luquin, N.; Navarro-Otano, J. The Endocannabinoid System in Cardiovascular Function: Novel Insights and Clinical Implications. Clin Auton Res 2018, 28 (1), 35–52.
https://doi.org/10.1007/s10286-017-0488-5
(122) Malinowska, B.; Baranowska-Kuczko, M.; Schlicker, E. Triphasic Blood Pressure Responses to Cannabinoids: Do We Understand the Mechanism? Br J Pharmacol 2012, 165 (7), 2073–2088.
https://doi.org/10.1111/j.1476-5381.2011.01747.x
(123) The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease - PMC.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554803/ (accessed 2024-04-06)
(124) The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies - PubMed.
https://pubmed.ncbi.nlm.nih.gov/33998900/ (accessed 2024-04-07)
(125) The Protective Mechanism of Cannabidiol in Cardiac Injury: A Systematic Review of Non-Clinical Studies - PubMed. https://pubmed.ncbi.nlm.nih.gov/31291873/ (accessed 2024-04-06).
(126) Stanley, C. P.; Hind, W. H.; O’Sullivan, S. E. Is the Cardiovascular System a Therapeutic Target for Cannabidiol? Br J Clin Pharmacol 2013, 75 (2), 313–322. https://doi.org/10.1111/j.1365-2125.2012.04351.x
(127) Feng, Y.; Chen, F.; Yin, T.; Xia, Q.; Liu, Y.; Huang, G.; Zhang, J.; Oyen, R.; Ni, Y. Pharmacologic Effects of Cannabidiol on Acute Reperfused Myocardial Infarction in Rabbits: Evaluated With 3.0T Cardiac Magnetic Resonance Imaging and Histopathology. J Cardiovasc Pharmacol 2015, 66 (4), 354–363.
https://doi.org/10.1097/FJC.0000000000000287
(128) A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study - PubMed. https://pubmed.ncbi.nlm.nih.gov/28614793/ (accessed 2024-04-06)
(129) Durst, R.; Danenberg, H.; Gallily, R.; Mechoulam, R.; Meir, K.; Grad, E.; Beeri, R.; Pugatsch, T.; Tarsish, E.; Lotan, C. Cannabidiol, a Nonpsychoactive Cannabis Constituent, Protects against Myocardial Ischemic Reperfusion Injury. Am J Physiol Heart Circ Physiol 2007, 293 (6), H3602-3607.
https://doi.org/10.1152/ajpheart.00098.2007
(130) Kováčik, A.; Kopečná, M.; Vávrová, K. Permeation Enhancers in Transdermal Drug Delivery: Benefits and Limitations. Expert Opin Drug Deliv 2020, 17 (2), 145–155. https://doi.org/10.1080/17425247.2020.1713087
(131) Chia, C. W.; Carlson, O. D.; Liu, D. D.; González-Mariscal, I.; Santa-Cruz Calvo, S.; Egan, J. M. Incretin Secretion in Humans Is under the Influence of Cannabinoid Receptors. Am J Physiol Endocrinol Metab 2017, 313 (3), E359–E366.
https://doi.org/10.1152/ajpendo.00080.2017
(132) Hammell, D. C.; Zhang, L. P.; Ma, F.; Abshire, S. M.; McIlwrath, S. L.; Stinchcomb, A. L.; Westlund, K. N. Transdermal Cannabidiol Reduces Inflammation and Pain-Related Behaviours in a Rat Model of Arthritis. Eur J Pain 2016, 20 (6), 936–948.
https://doi.org/10.1002/ejp.818
(133) Lehmann, C.; Fisher, N. B.; Tugwell, B.; Szczesniak, A.; Kelly, M.; Zhou, J. Experimental Cannabidiol Treatment Reduces Early Pancreatic Inflammation in Type 1 Diabetes. Clin Hemorheol Microcirc 2016, 64 (4), 655–662. https://doi.org/10.3233/CH-168021
(134) Sunda, F.; Arowolo, A. A Molecular Basis for the Anti-Inflammatory and Anti-Fibrosis Properties of Cannabidiol. FASEB J 2020, 34 (11), 14083–14092. https://doi.org/10.1096/fj.202000975R
(135) El-Remessy, A. B.; Al-Shabrawey, M.; Khalifa, Y.; Tsai, N.-T.; Caldwell, R. B.; Liou, G. I. Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes. Am J Pathol 2006, 168 (1), 235–244.
(136) CBD & Diabetes | ADA. https://diabetes.org/health-wellness/cbd-and-diabetes (accessed 2024-04-06).
(137) DeFronzo, R. A. Combination Therapy with GLP-1 Receptor Agonist and SGLT2 Inhibitor. Diabetes Obes Metab 2017, 19 (10), 1353–1362.
https://doi.org/10.1111/dom.12982
(138) Scheen, A. J. Dual GIP/GLP-1 Receptor Agonists: New Advances for Treating Type-2 Diabetes. Ann Endocrinol (Paris) 2023, 84 (2), 316–321.
https://doi.org/10.1016/j.ando.2022.12.423
(139) Nogueiras, R.; Veyrat-Durebex, C.; Suchanek, P. M.; Klein, M.; Tschöp, J.; Caldwell, C.; Woods, S. C.; Wittmann, G.; Watanabe, M.; Liposits, Z.; Fekete, C.; Reizes, O.; Rohner-Jeanrenaud, F.; Tschöp, M. H. Peripheral, but Not Central, CB1 Antagonism Provides Food Intake–Independent Metabolic Benefits in Diet-Induced Obese Rats. Diabetes 2008, 57 (11), 2977–2991. https://doi.org/10.2337/db08-0161
(140) Nam, D. H.; Lee, M. H.; Kim, J. E.; Song, H. K.; Kang, Y. S.; Lee, J. E.; Kim, H. W.; Cha, J. J.; Hyun, Y. Y.; Kim, S. H.; Han, S. Y.; Han, K. H.; Han, J. Y.; Cha, D. R. Blockade of Cannabinoid Receptor 1 Improves Insulin Resistance, Lipid Metabolism, and Diabetic Nephropathy in Db/Db Mice. Endocrinology 2012, 153 (3), 1387–1396. https://doi.org/10.1210/en.2011-1423
(141) Bajzer, M.; Olivieri, M.; Haas, M. K.; Pfluger, P. T.; Magrisso, I. J.; Foster, M. T.; Tschöp, M. H.; Krawczewski-Carhuatanta, K. A.; Cota, D.; Obici, S. Cannabinoid Receptor 1 (CB1) Antagonism Enhances Glucose Utilisation and Activates Brown Adipose Tissue in Diet-Induced Obese Mice. Diabetologia 2011, 54 (12), 3121–3131. https://doi.org/10.1007/s00125-011-2302-6
(142) Mattes, R. G.; Espinosa, M. L.; Oh, S. S.; Anatrella, E. M.; Urteaga, E. M. Cannabidiol (CBD) Use in Type 2 Diabetes: A Case Report. Diabetes Spectrum 2021, 34 (2), 198–201. https://doi.org/10.2337/ds20-0023
(143) Rafailovska, E.; Xhemaili, E.; Naumovska, Z.; Gigopulu, O.; Miova, B.; Suturkova, L.; Stefkov, G., Unlocking the Antidiabetic Potential of CBD: In Vivo Preclinical Studies. Pharmaceuticals 2025, 18 (4), 446. https://doi.org/10.3390/ph18040446
(144) Stella, B.; Baratta, F.; Della Pepa, C.; Arpicco, S.; Gastaldi, D.; Dosio, F., Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain. Drugs 2021, 81 (13), 1513–1557.
https://doi.org/10.1007/s40265-021-01579-x
(145) CANNABIDIOL (CBD): Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews. https://www.webmd.com/vitamins/ai/ingredientmono-1439/cannabidiol-cbd (accessed 2024-03-31).
(146) Paudel, K. S.; Hammell, D. C.; Agu, R. U.; Valiveti, S.; Stinchcomb, A. L. Cannabidiol Bioavailability after Nasal and Transdermal Application: Effect of Permeation Enhancers. Drug Dev Ind Pharm 2010, 36 (9), 1088–1097.
https://doi.org/10.3109/03639041003657295
(147) Sholler, D. J.; Schoene, L.; Spindle, T. R. Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies. Curr Addict Rep 2020, 7 (3), 405–412.
https://doi.org/10.1007/s40429-020-00326-8
(148) Madden, K.; Tanco, K.; Bruera, E. Clinically Significant Drug-Drug Interaction Between Methadone and Cannabidiol. Pediatrics 2020, 145 (6), e20193256.
https://doi.org/10.1542/peds.2019-3256
(149) Geffrey, A. L.; Pollack, S. F.; Bruno, P. L.; Thiele, E. A. Drug-Drug Interaction between Clobazam and Cannabidiol in Children with Refractory Epilepsy. Epilepsia 2015, 56 (8), 1246–1251.
Downloads
Published
Versions
- 2026-03-27 (3)
- 2025-12-26 (2)
- 2025-12-25 (1)
How to Cite
Issue
Section
License
Copyright (c) 2025 Elona Xhemaili, Elena Rafailovska, Zorica Naumovska, Olga Gigopulu, Biljana Miova, Ljubica Suturkova, Gjoshe Stefkov
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
